Latest Conference Coverage

Insights on Gut Bacteria and Cognitive Health from Middle-Aged Adults: Jazmyn Muhammad, BS

The clinical research associate at the University of Texas Health Science Center at San Antonio discussed a study that explores the relationship between cognitive function and gut microbiome structure in middle-aged adults from the Framingham Heart Study cohort. [WATCH TIME: 4 minutes]

Advancing Research With Remote Blood Collection for Alzheimer Biomarkers: Hanna Huber, PhD

The researcher in the department of neurochemistry at the University of Gothenburg in Sweden discussed bloodspot cards as a promising method for collecting blood samples in Alzheimer disease research. [WATCH TIME: 4 minutes]

The Power of Diversity and Expanding the Genetic Landscape in Alzheimer Disease Research: Adam Naj, PhD

The genetic epidemiologist at the University of Pennsylvania talked about a collaboration of sites and analysis groups across the US to create a vast collection of genetic data on patients living with Alzheimer disease. [WATCH TIME: 5 minutes]

Diversifying Research and Improving Asian Representation With New Cohort Study for Alzheimer Disease

Li-San Wang, PhD, the Peter C. Nowell, MD, professor of pathology and laboratory medicine, Perelman School of Medicine at the University of Pennsylvania, discussed a study that aims to address the underrepresentation of Asian populations in Alzheimer disease research.

Diagnosing Alzheimer Disease With New Blood Tests in Primary Care Settings: Sebastian Palmqvist, MD, PhD

The associate professor of neuroscience at Lund University in Sweden discussed findings from a study of a new blood test examining biomarkers which demonstrated a high accuracy in identifying Alzheimer disease pathology. [WATCH TIME: 5 minutes]

Promising Therapeutic Developments for TDP-Related Pathologies: Sílvia Porta, PhD

The research assistant professor, pathology and laboratory medicine, University of Pennsylvania, talked about the ongoing research in her lab on understanding the mechanisms and consequences of TDP-43 aggregation in Alzheimer Disease. [WATCH TIME: 4 minutes]

Positive Progress Reported in ANeED Study of Ambroxol in Dementia With Lewy Bodies

Several patients have completed the 18-month trial and have moved on to the open-label extension, where they will be followed for an additional 12 months.

Revolutionizing Alzheimer Disease Diagnosis with Blood Biomarkers: Nicholas Ashton, PhD

The associate professor of neurochemistry at the University of Gothenburg in Sweden talked about a pilot study that explored the potential of finger prick tests to remotely collect blood and provide reliable biomarker results for Alzheimer disease diagnosis. [WATCH TIME: 5 minutes]

Overcoming Complexities With Cognitive Screening in Primary Care Centers: Nicole Fowler, PhD

The director of research for internal medicine and geriatrics at Indiana University School of Medicine provided perspective on ways to effectively streamline cognitive screening in timely and accurate manor. [WATCH TIME: 4 minutes]

Mortality Risk Significantly Increased With New Opioid Use in Older Adults With Dementia

In total, 33% of the study participants died within 180 days after initiating their first opioid prescription, compared with 6.4% of those unexposed.

Insights on Uncovering the Gut-Brain Interaction and Cognitive Function in Alzheimer Disease

Chaoran Ma, MD, PhD, assistant professor at University of Massachusetts Amherst, talked about the association between bowel movement frequency, the gut microbiome, and cognitive function in patients living with dementia.

Opioid Use and Mortality Risk in Older Patients with Dementia: Christina Jensen-Dahm, MD, PhD

The neurologist in the Danish Dementia Research Center at Rigshospitalet in Copenhagen, Denmark, discussed a cohort study that examined the association between opioid use and the risk of mortality in an older patient population living with dementia. [WATCH TIME: 5 minutes]

Potential Benefit of Nicotinamide Observed in Proof-Of-Concept Trial of Alzheimer Disease

Change in phosphorylated tau231, the primary outcome, favored nicotinamide despite not reaching statistical significance.

Alzheimer Disease Pipeline Update: Inside Look at Promising Agents

With the recent approval of lecanemab (Leqembi; Eisai), NeurologyLive took a closer look at the Alzheimer pipeline, and the potential agents clinicians should keep an eye on in the coming years.

Revised Mediterranean Diet Shows No Significant Impact on Cognition, MRI Outcomes in Older Persons

Using a cohort of more than 600 cognitively normal adults, the MIND diet failed to outperform a control diet of mild caloric restriction on several outcomes, including cognition and hippocampal volumes.

Implications of Rising Alzheimer Disease Prevalence Across US Counties: Kumar B. Rajan, PhD

The professor in the department of internal medicine at RUSH Medical College talked about estimating the prevalence of Alzheimer disease to uncover the variability in disease prevalence at a micro-level and its implications for public health programs. [WATCH TIME: 5 minutes]

NeuroVoices: Dustin Hammers, PhD, on Comparative Performance of Cognitive Screening Techniques

The associate professor of neurology at the Indiana University School of Medicine provided commentary on a study comparing traditional cognitive screening methods and the Linus Health Digital Clock and Recall test.

Pimavanserin Safe in Elderly Patients With Neurodegenerative Disease-Related Neuropsychiatric Symptoms

In a cohort of nearly 800 frail adults and elderly patients with neuropsychiatric symptoms, pimavanserin showed similar rates of treatment-related adverse events and discontinuations because of TEAEs to placebo.

Donanemab Demonstrates Slowing of Alzheimer Disease Progression in Phase 3 TRAILBLAZER-ALZ 2 Trial

The clinical relevance of donanemab was demonstrated through a slowing of clinical decline, stability of clinical symptoms, lowered risk of advancement to next clinical stage, and lower risk of meaningful within-patient change.

Differences in Available Cognitive Screening Tools: Dustin Hammers, PhD

The associate professor of neurology at the Indiana University School of Medicine provided insight on the distinguishable characteristics of certain cognitive screening tools and the advantages to each. [WATCH TIME: 3 minutes]

Preparing Primary Care Centers for New Wave of Alzheimer Agents: Nicole Fowler, PhD, MHSA

The director of research for internal medicine and geriatrics at Indiana University School of Medicine provided perspective on navigating challenges with newly approved treatments for Alzheimer disease, and using resources efficiently. [WATCH TIME: 5 minutes]

DCR Test Comparable to Other Traditional Cognitive Screening Assessments, With Less Administration Time

A comparison between impaired scores on Digital Clock and Recall and impaired scores on Montreal Cognitive Assessment produced a 76% concordance.

Caregivers Perceived Reciprocity Reduces Behavioral Symptoms in Patients With Alzheimer Disease

According to diary data, caregiver's perceived reciprocity showed a substantial direct influence on the occurrence of behavioral symptoms on both the current day and the subsequent day for patients with Alzheimer disease and related dementias.

Preclinical Research on CRISPR-Based Gene Editing for Alzheimer Disease Treatment: Brent D. Aulston, PhD

The postdoctoral fellow at the University of California San Diego discussed using CRISPR-based gene editing to alter the amyloid precursor protein gene in mice models with symptoms of Alzheimer disease. [WATCH TIME: 5 minutes]

Patient-Centric, Knowledge-Driven: Advanced Therapeutics in Movement and Related Disorders™ Congress

Clinicians must be armed with fact-based information on all treatment options especially newer medications and technologies—good clinical care must be both patient-centric and knowledge-driven.

Effect of Social Determinants of Health on Brain Aging in Minoritized Patients with Multiple Sclerosis: Cristina A.F. Román, PhD

The National Multiple Sclerosis Society sponsored research fellow at Kessler Foundation talked about a research project that investigates the differences in brain structure and aging metrics among patients with multiple sclerosis from differing racial and ethnic backgrounds. [WATCH TIME: 5 minutes]

Identifying Effective Big Data Techniques to Address Heterogeneity in Migraine: Ali Ezzati, MD

The director of the Neuroinformatics Program at the University of California, Irvine, discussed complexities with different machine learning algorithms in migraine research, including findings from the AMPP study. [WATCH TIME: 5 minutes]

Generalized Myasthenia Gravis Symptom Severity Reduced Through Ravulizumab Treatment

The highest proportions of patients with severe ocular impairment at baseline showed greater improvements in symptom severity on ravulizumab in comparison with placebo after 26 weeks.

Zilucoplan Demonstrates Consistent Efficacy in Phase 3 RAISE Study of Generalized Myasthenia Gravis

Nearly half of patients treated with zilucoplan were considered responders on Myasthenia Gravis Activities of Daily Living (MG-ADL) at the first week, suggesting a rapid onset of efficacy.

Examining Depression and Suicidality in Pediatric Patients With MS: Sarah C. Stoney, MSW, LSW

The social worker in the Pediatric Multiple Sclerosis Clinic at Children's Hospital of Philadelphia talked about depression and suicidality rates in pediatric patients with multiple sclerosis. [WATCH TIME: 5 minutes]